Nike Inc. (NKE) is touted to post its second-quarter results on Thursday, Dec. 20, after the market closes its regular trading for the day.
The Street expects the sports apparel maker to earn $0.45 per share on revenue of $9.16 billion for the quarter.
In the previously reported quarter, even though Nike’s North America segment recovered as total earnings jumped on strong revenue growth, the stock dropped sharply on higher costs and squeeze on margin.
The sneaker maker, then, was facing intense scrutiny over its controversial advertisement featuring Colin Kaepernick. However, the results exceeded Wall Street projections. Revenues of the NIKE brand then gained 10% and Converse moved up 7% during the previous quarter.
Back in May, CEO Mark Parker faced immense pressure over a sexual harassment scandal involving some senior executives, as several of them were shown the door after an in-house investigation. Trevor Edwards, the former president who was a prospective successor to Parker, was among those who stepped down.
Its ad campaign later in the year involving Kaepernick had also triggered a selloff initially, but the stock bounced back later.
The North American market remains a challenge for sportswear manufacturers and footwear companies in general, with changing shopping habits and stiff competition. Nike’s competitor, Under Armour (UA) has been hit hard, with the launch of some of its premium brands fizzling.
Along with its ongoing organizational restructuring, Under Armour seems to have failed the confidence of investors, as its stock plunged about 10% last Wednesday when its investor day presentation hinted at low single-digit revenue growth in North America in the next five years.
Given that Nike also looks to its North America business for a big chunk of its top line, it might be a good time to focus more on international business.
Browse through our earnings calendar and get all scheduled earnings announcements, analyst/investor conference, and much more!
Most Popular
Intensity Therapeutics is establishing a new field of localized cancer reduction: CEO
Intensity Therapeutics, Inc. (NASDAQ: INTS) is a clinical biotechnology company engaged in the discovery development, and commercialization of first-in-class cancer drugs that attenuate tumors with minimal side effects while training
INTU Earnings: Intuit Q1 2025 adj. profit rises on higher revenues
Financial technology company Intuit Inc. (NASDAQ: INTU) Thursday announced results for the first quarter of 2025, reporting a modest increase in adjusted earnings. The Mountain View-headquartered company’s first-quarter revenue came
Riding the AI wave, Nvidia looks set to stay on the high-growth path
After delivering strong results for the third quarter, Nvidia Corporation (NASDAQ: NVDA) this week said the launch of its new-generation Blackwell chip is on track. The company is thriving on
